Springer Nature
Browse
13024_2020_362_MOESM1_ESM.docx (199.71 kB)

Additional file 1 of Circulating cell-free mitochondrial DNA levels in Parkinson’s disease are influenced by treatment

Download (199.71 kB)
journal contribution
posted on 2020-02-19, 05:16 authored by Hannah Lowes, Angela Pyle, Mauro Santibanez-Koref, Gavin Hudson
Additional file 1 Table 1. Demographic and clinical charateristics of PD patients and controls at baseline (0 months) and 36 months. Table 2. Comparison of ccf-mtDNA levels to clinical severity ratings and PD-related phenotypes at 0- and 36-months. Table 3. Frequency of ICICLE-PD patient treatment at 0 and 18 months. Table 4. Comparsion of ccf-mtDNA levels between PD-related comorbidities at 0- and 36-months. Figure 1. Individual changes in ccf-mtDNA copy number, from 0 to 36 months. Figure 2. Correlation of ccf-mtDNA levels to LEDD for merged PPMI-PD and ICICLE-PD data. Figure 3. Ccf-mtDNA levels associate with PD specific treatments in ICICLE-PD. Figure 4. Linear regression of mean ccf-mtDNA levels versus treatment duration for each PD treatment

Funding

Wellcome Trust

History

Usage metrics

    Molecular Neurodegeneration

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC